Scinopharm Taiwan (TPE:1789) Notes Receivable: NT$0 Mil (As of Dec. 2025)


TPE:1789 Scinopharm Taiwan Ltd TPE:1789
75 GF Score
Price NT$20.80
GF Value NT$27.20
Valuation Modestly Undervalued
! 8 Warning Signs
View Full Analysis

What is Scinopharm Taiwan Notes Receivable?

Scinopharm Taiwan TPE:1789 +0.96% 75 Notes Receivable is NT$0 Mil as of Dec. 2025. GuruFocus rates TPE:1789 with a GF Score™ of 75/100 and a GF Value™ of NT$27.20 (Modestly Undervalued). The stock has 8 warning signs investors should review.

Scinopharm Taiwan's Notes Receivable for the quarter that ended in Dec. 2025 was NT$0 Mil.

Scinopharm Taiwan Notes Receivable Related Terms

Scinopharm Taiwan Notes Receivable Historical Data

* Premium members only.

The historical data trend for Scinopharm Taiwan's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Scinopharm Taiwan Notes Receivable Chart

Scinopharm Taiwan Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Scinopharm Taiwan Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
TPE:1789
75GF Score
Scinopharm Taiwan Ltd TPE:1789
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Scinopharm Taiwan Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of NT$0 Mil mean?
Scinopharm Taiwan (TPE:1789) has a Notes Receivable of NT$0 Mil as of Dec. 2025. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Scinopharm Taiwan and its competitors.
Is Scinopharm Taiwan's Notes Receivable too high?
Scinopharm Taiwan's current Notes Receivable is NT$0 Mil. Overall, Scinopharm Taiwan has a GF Score™ of 75/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Scinopharm Taiwan's Notes Receivable compare to ZTS and UTHR?
Scinopharm Taiwan's Notes Receivable of NT$0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Drug Manufacturers company?
A good Notes Receivable depends on the Drug Manufacturers industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Scinopharm Taiwan and its competitors. Scinopharm Taiwan's current Notes Receivable is NT$0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scinopharm Taiwan stock overvalued right now?
Based on GuruFocus' analysis, Scinopharm Taiwan (TPE:1789) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$27.20, compared to a current price of NT$20.80 — trading 23.5% below its estimated fair value. The current Notes Receivable is NT$0 Mil. Scinopharm Taiwan's overall GF Score™ is 75/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Scinopharm Taiwan (TPE:1789), the current Notes Receivable is NT$0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Scinopharm Taiwan (TPE:1789) Overvalued in 2026?

Based on GuruFocus' analysis, Scinopharm Taiwan stock appears to be undervalued. The current stock price of NT$20.80 is trading 23.5% below its estimated GF Value™ of NT$27.20. GuruFocus considers Scinopharm Taiwan to be Modestly Undervalued.

Key valuation signals for TPE:1789:

  • Notes Receivable: NT$0 Mil
  • GF Value™: NT$27.20 vs. price of NT$20.80 (23.5% below fair value)
  • GF Score™: 75/100 with 8 warning signs

No single metric tells the full story. See the TPE:1789 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Scinopharm Taiwan Business Description

Address Nan-Ke 8th Road, No. 1, Southern Taiwan Science Park, Shan-Hua, Tainan, TWN, 74144
Scinopharm Taiwan Ltd is mainly engaged in the manufacture of western medicines and other chemical materials, biological technology services, intellectual property rights, international trade, and the research, development, production, manufacture, and sales of Active Pharmaceutical Ingredients (API), albumin medicines, oligonucleotide medicines, peptide medicines, injections, and new small molecule drugs. The Company also provides related consulting and technical services and international trade for the above products. In addition, the Company sells chemical material reprocessed from material recycled from the Company's manufacturing process.
75GF Score

Get the complete analysis for TPE:1789

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$20.80
Price
NT$27.20
GF Value